Marketplace Pulse: Coverage of Obesity Therapies in State-Regulated Markets The Marketplace Pulse series provides expert insights on timely policy topics related to the health insurance marketplaces
2 Earlier this week, Reuters also confirmed 3 that Noom would continue to sell the compounded semaglutide moving forward
In animal experiments, GLP-1RAs induce frequent vomiting, whereas GIP receptor agonists do not
In my practice, I use lower doses than the maximum, combined with therapy, lifestyle changes, and attention to factors like inflammation and stress
Judging a dose's effectiveness before steady state leads to premature escalation
One critical aspect often overlooked is the risk of muscle loss and its negative impact on metabolic health and longevity